Entero Therapeutics Inc.
13F holders, Q1 2025 (March 31)8holders −1
2new positions
3sold out
$0.47avg. 13F price*
At the end of Q1 2025, 8 institutions reported holding Entero Therapeutics Inc. in their 13F filings, down 1 from Q4 2024. 2 opened new positions and 3 sold out. The largest holders were UBS Group AG ($28K), Geode Capital Management, LLC ($18K) and HRT Financial LP ($13K).
- Company
- Entero Therapeutics Inc.
- CUSIP
- 33749P408
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $18K |
| Exits | 3 | $23K |
All 13F filers, Q4 2024 → Q1 2025: 106,561 shares bought and 37,219 shares sold, net +69,342 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| UBS Group AG | 0.00% | Add +670.3% | 57,975 | $28K |
| Geode Capital Management, LLC | 0.00% | Add +84.1% | 36,560 | $18K |
| HRT Financial LP | 0.00% | New | 28,602 | $13K |
| JB Capital LLC | 0.00% | New | 10,000 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +0.1% | 5,070 | $2K |
| SBI Securities Co., Ltd. | 0.00% | Add +31.9% | 3,307 | $2K |
| Bank of America Corp. | 0.00% | Add +2.6% | 40 | $19 |
| US Bancorp \de | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is ENTERO THERAPEUTICS INC's weight in each manager's 13F, not the share of Entero Therapeutics Inc. the manager owns.